5 results on '"Nicolas Poulalhon"'
Number of results to display per page
Search Results
2. Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group
- Author
-
Pierre-Emmanuel Stoebner, Christophe Bedane, A. Jannic, Marc Dumas, Marie Moncourier, Sandrine Mansard, Anne-Bénédicte Duval-Modeste, David Solub, Sophie Darras, Suzanne Devaux, Julia Sanchez, Nicolas Meyer, Laurent Misery, Valentine Heidelberger, Raoul Triller, Ingrid Kupfer-Bessaguet, Nathalie Beneton, Florence Brunet-Possenti, Gaëlle Quéreux, E. Maubec, Sophie Dalac, François Skowron, Safia Abed, Caroline Gaudy-Marqueste, Laurent Mortier, Monica Dinulescu, F. Herms, Lucie Peuvrel, Marouane Boubaya, Candice Hober, Pierre Guillet, Mahtab Samimi, Yves Reguerre, Nicolas Poulalhon, Anne Pham-Ledard, Stéphanie Catala, Eve-Marie Neidhardt, Romain Lesbazeilles, Jean-Philippe Arnault, Brigitte Dréno, Olivier Collard, Philippe Celerier, Julie De Quatrebarbes, Youssef Tazi, Pierre Combe, Caroline Jacobzone, Élodie Archier, F. Aubin, Dominique Spaeth, Clémence Berthin, Nora Kramkimel, Florent Grange, Candice Lesage, Lisa Fredeau, A. Schoeffler, Marc Pracht, Bertille Bonniaud, Laure Cesaire, Maxime Etienne, Olivier Lauche, CHU Lille, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Bordeaux [Bordeaux], Université de Bordeaux (UB), Hopital Saint-Louis [AP-HP] (AP-HP), Hôpital Saint-Louis de La Rochelle (CH La Rochelle), Université de Bourgogne (UB), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Le Mans (CH Le Mans), Hôpital Pontchaillou, Hôpital Henri Mondor, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Léon Bérard [Lyon], Hôpital Saint-Joseph [Marseille], Centre hospitalier universitaire de Nantes (CHU Nantes), Université de Nantes (UN), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Clinical and Translational Research in Skin Cancer (CRCINA-ÉQUIPE 2), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Cochin [AP-HP], Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier de Valence (CH DE VALENCE), Centre hospitalier de Valence, CH Annecy Genevois, CHU de Nîmes, Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Amiens-Picardie, Hopital d'instruction des armées Sainte-Anne [Toulon] (HIA), CH Boulogne sur Mer, Hôpital Robert Ballanger [Aulnay-sous-Bois], Centre Hospitalier de la Côte Basque (CHCB), Centre Hospitalier Universitaire [Grenoble] (CHU), Université de Bretagne Occidentale, CHU Clermont-Ferrand, Centre Hospitalier Intercommunal de Cornouaille (CHIC), Centre Hospitalier Intercommunal de Cornouaille [Quimper] (CHI Cornouaille [Quimper]), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Georges Renon [Niort] (CH Georges Renon Niort), Clinique Saint Pierre, Perpignan, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Infectiologie et Santé Publique (UMR ISP), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Clinique Sainte Anne [Strasbourg], Centre d'Oncologie de Gentilly, Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut hospitalier Franco-Britannique [Levallois-Perret], CH René Dubos, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Pôle Santé Léonard de Vinci, Partenaires INRAE, Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), CHU Limoges, Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), UFR Santé, Médecine et Biologie Humaine (UFR SMBH), Université Sorbonne Paris Nord, Toxicité environnementale, cibles thérapeutiques, signalisation cellulaire (T3S - UMR_S 1124), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Toulouse - CHU Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), Le CHCB, Centre Hospitalier de la Côte Basque, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPC), Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)
- Subjects
Cancer Research ,medicine.medical_specialty ,cutaneous squamous cell carcinoma ,Locally advanced ,Best Overall Response ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Gastroenterology ,Article ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Overall survival ,Medicine ,Adverse effect ,Group performance ,RC254-282 ,Immune status ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Mean age ,medicine.disease ,chronic dermatosis ,Toxic epidermal necrolysis ,3. Good health ,immunocompromised ,real-life setting ,Oncology ,030220 oncology & carcinogenesis ,PD-1–blocking antibody ,cemiplimab ,business ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology - Abstract
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%, partial, 29%). With median follow-up at 12.6 months, median PFS was 7.9 months, and median OS and DOR were not reached. One-year OS was 73% versus 36%, respectively, for patients with PS <, 2 versus ≥ 2. Multivariate analysis retained PS ≥ 2 as being associated during the first 6 months with PFS and OS. Head-and-neck location was associated with longer PFS. Immune status had no impact. Severe treatment-related adverse events occurred in 9% of the patients, including one death from toxic epidermal necrolysis. Cemiplimab real-life safety and efficacy support its use for la/mCSCCs. Patients with PS ≥ 2 benefited less from cemiplimab, but it might represent an option for immunocompromised patients.
- Published
- 2021
- Full Text
- View/download PDF
3. Acute renal failure associated with the new BRAF inhibitor vemurafenib: A case series of 8 patients
- Author
-
S. Amet, Gilbert Deray, Nicolas Poulalhon, Morgane Gosselin, Valérie Garrigue, Vincent Launay-Vacher, Thibault Fraisse, Sarah Zimner-Rapuch, and Nicolas Janus
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Melanoma ,Dacarbazine ,medicine.medical_treatment ,Renal function ,Cancer ,medicine.disease ,Surgery ,Targeted therapy ,Nephrotoxicity ,Internal medicine ,medicine ,Vemurafenib ,business ,medicine.drug ,Kidney disease - Abstract
BACKGROUND Vemurafenib is a BRAF inhibitor that has become the cornerstone of metastatic or inoperable melanoma therapy since its approval in 2011 in the United States and 2012 in Europe. This targeted therapy has shown impressive results in terms of increased progression-free and overall survival as compared to dacarbazine. The safety profile did not include any renal manifestations at that time. METHODS This report is the first case series of 8 patients who experienced significant to severe renal insufficiency under vemurafenib treatment. RESULTS This case series shows that vemurafenib may induce potentially severe acute renal failure, including renal sequelae and persistent kidney disease in some cases. CONCLUSIONS Further studies are needed to investigate the effects of vemurafenib on the kidneys. Meanwhile, renal function should be closely monitored in treated patients for early detection of any renal dysfunction occurrence. Cancer 2014;120:2158–2163. © 2014 American Cancer Society.
- Published
- 2014
- Full Text
- View/download PDF
4. Stevens–Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy
- Author
-
Alexis Sidoroff, Maja Mockenhaupt, Nicolas Poulalhon, Batya Davidovici, Jean-Paul Fagot, Peggy Sekula, and Laurence Valeyrie-Allanore
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Radiation-Protective Agents ,Amifostine ,Head and neck radiotherapy ,medicine ,Adverse Drug Reaction Reporting Systems ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Prospective cohort study ,Aged ,Chemotherapy ,business.industry ,Hematology ,Middle Aged ,Prodrug ,medicine.disease ,Dermatology ,Cytoprotection ,Toxic epidermal necrolysis ,Europe ,Radiation therapy ,stomatognathic diseases ,Oncology ,Head and Neck Neoplasms ,Stevens-Johnson Syndrome ,Female ,business ,medicine.drug - Abstract
Amifostine is an organic thiophosphate prodrug used for cytoprotection against toxic effects of radiotherapy and chemotherapy. In a European prospective study of SJS/TEN, six patients were suspected to have SJS/TEN associated with amifostine. Our findings suggest that the risk of life-threatening cutaneous adverse reactions to amifostine could be significantly increased.
- Published
- 2008
- Full Text
- View/download PDF
5. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil
- Author
-
Franck Verrecchia, Dominique Farge, Isabelle Madelaine, Nina Roos, Nicolas Poulalhon, Alain Mauviel, Bases Moleculaires de l'Homeostasie Cutanee : Inflammation, Reparation et Cancer, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Médecine Interne [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Pharmacie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Verrecchia, Franck
- Subjects
medicine.medical_treatment ,MESH: Collagen Type I ,0302 clinical medicine ,Fibrosis ,Cell Movement ,MESH: Cell Movement ,Cells, Cultured ,0303 health sciences ,MESH: Gene Expression Regulation ,3. Good health ,medicine.anatomical_structure ,Immunosuppressive drug ,MESH: Fibrosis ,Molecular Medicine ,MESH: Immunosuppressive Agents ,Matrix Metalloproteinase 1 ,Myofibroblast ,Type I collagen ,Immunosuppressive Agents ,medicine.drug ,MESH: Cells, Cultured ,[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,MESH: Actins ,Mycophenolic acid ,Collagen Type I ,03 medical and health sciences ,medicine ,[SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology ,Humans ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,Fibroblast ,[SDV.BC] Life Sciences [q-bio]/Cellular Biology ,030304 developmental biology ,MESH: Mycophenolic Acid ,030203 arthritis & rheumatology ,Pharmacology ,MESH: Humans ,business.industry ,[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology ,Fibroblasts ,Mycophenolic Acid ,medicine.disease ,Actins ,Transplantation ,MESH: Matrix Metalloproteinase 1 ,Gene Expression Regulation ,MESH: Fibroblasts ,Immunology ,Cancer research ,business ,Wound healing ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology - Abstract
International audience; The immunosuppressive drug mycophenolate mofetil (MMF) is used to prevent organ rejection after transplantation and has shown some efficacy to prevent the fibrotic complications that occur during autoimmune diseases such as systemic sclerosis or during graft-versus-host disease (GVHD). We tested the hypothesis that MMF may exert direct effects on fibroblast extracellular matrix remodeling. Incubation of human lung fibroblast cultures with MMF led to dose- and time-dependent reduction in the synthesis and expression of type I collagen. Inhibition of COL1A1 and COL1A2 mRNA steady-state levels occurred at the level of transcription via repression of their promoters. In contrast, MMF significantly enhanced the expression and the synthesis of interstitial collagenase (matrix metalloproteinase-1). MMF was also found to diminish the capacity of fibroblast to contract mechanically unloaded collagen lattices and to reduce the synthesis of alpha-smooth muscle actin, a marker of the contractile myofibroblast phenotype. In addition, MMF diminished the fibroblasts motility. In conclusion, we provide novel mechanism by which MMF alters fibroblast functions important for wound healing and implicated in the development of tissue fibrosis, e.g., collagen production, extracellular matrix contraction, and cell migration. Such properties may contribute to the beneficial therapeutic effects of MMF against fibrotic lesions developing in systemic sclerosis or during GVHD.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.